The data used for this study were obtained from Australian Capital Territory (ACT) Pathology and are owned by the ACT Government Health Directorate. Conditions of ethical approval do not allow us to distribute or make available patient data directly to other parties. Applications for data access can be made by contacting the ACT Pathology data custodian at <actpathology@act.gov.au> and researchers must have their study protocol approved by the ACT Health Human Research Ethics Committee.

Introduction {#sec001}
============

Urinary tract infections (UTIs) are predominantly bacterial infections affecting people both in the community and in hospitals \[[@pone.0164306.ref001]\]. Over 80% are caused by *Escherichia coli (E*. *coli)*, a Gram negative bacillus \[[@pone.0164306.ref002]\]. Data from the combined National Ambulatory Health Care Surveys in the United States (US) for 2009--2010 showed that UTIs accounted for approximately 9.8 million visits to ambulatory care settings such as primary care, outpatient and emergency departments \[[@pone.0164306.ref003]\]. Visits due to UTI were estimated to be 0.8% of all ambulatory care visits \[[@pone.0164306.ref003]\]. In Australia, national data on UTI are unavailable but recent estimates from 82 hospitals and 17 aged care facilities reported a point prevalence of 1.4% and 1.5% respectively for healthcare associated UTIs \[[@pone.0164306.ref004]\].

While UTIs are a major infection burden globally, the growing problem of antimicrobial resistance (AMR) can result in treatment failures and increased cost of healthcare \[[@pone.0164306.ref005]\]. There is evidence to show that the AMR pattern of urinary *E*. *coli* is increasing \[[@pone.0164306.ref006]\]. In Switzerland, an analysis of urinary *E*. *coli* specimens obtained from a university hospital from 1997 to 2007 found an increasing trend in resistance to trimethoprim/sulfamethoxazole, ciprofloxacin and amoxycillin/clavulanic acid (from 17.4% to 21.3%, 1.8% to 15.9%, and 9.5% to 14.5%, respectively) \[[@pone.0164306.ref006]\]. The Australian Group on Antimicrobial Resistance (AGAR) which undertakes AMR prevalence surveys within Australia also noted a gradual rise in overall percentage of *E*. *coli* strains resistant to beta-lactam antibiotics and ciprofloxacin \[[@pone.0164306.ref007]\]. From 2009 to 2011, resistance of hospital-onset *E*. *coli* isolates to ampicillin and ciprofloxacin increased from 48% to 51% and 8% to 11% respectively \[[@pone.0164306.ref007]\]. Furthermore, the resistance rates of urinary *E*. *coli* to various antimicrobials show large inter-country variability \[[@pone.0164306.ref008]\]. Only a few studies have shown that *E*. *coli* resistance rates differ for hospital-acquired and community-acquired UTIs \[[@pone.0164306.ref009]--[@pone.0164306.ref011]\]. Measuring and comparing the levels of AMR in both hospital- and community-acquired UTIs is essential because although effects of AMR are mainly felt in healthcare facilities, the greatest use of antimicrobials occurs in the community \[[@pone.0164306.ref012]\]. Comparing resistance rates in hospital- and community-acquired UTIs may influence therapeutic recommendations for UTIs based on setting of acquisition.

The prevalence of AMR including hospital and community urinary *E*. *coli* resistance levels is not completely known in Australia. Obtaining this information is important because it not only provides knowledge about the health status of a population, but also contributes to disease management decisions \[[@pone.0164306.ref013]\]. This study describes the AMR temporal trends and seasonal variation of *E*. *coli* UTI over five years at an Australian tertiary hospital. The study also compares the prevalence of resistance between hospital- and community-acquired *E*. *coli* UTIs.

Materials and Methods {#sec002}
=====================

Study design and setting {#sec003}
------------------------

A retrospective cross sectional design was used. The study was conducted with data from ACT Pathology which is based at a tertiary referral hospital, the Canberra Hospital and Health Services. This is Australian Capital Territory's (ACT) main hospital which provides acute and specialist care services to over 600,000 people in the surrounding region. The 600 bed publicly-funded hospital which includes an emergency department and intensive care unit, offers a comprehensive range of health services such as acute inpatient and day services, outpatient services, women\'s and children\'s services and pathology services. Solid organ transplant services are not offered in Canberra.

Human research ethics approval was granted by ACT Health Human Research Ethics Committee's Low Risk Sub-Committee and Australian Catholic University Human Research Ethics Committee. Consent from patients was not obtained as a waiver of consent was granted by the ethics committees.

Urine sample and data collection {#sec004}
--------------------------------

The microbiology records of inpatients and those attending Canberra Hospital who had urine samples processed at ACT Pathology from January 2009 to December 2013 were retrospectively reviewed. Demographic data and clinical information such as date of birth, gender, admission date, specimen collection date and antimicrobial susceptibility test result were obtained from the microbiology laboratory database and administrative record system.

Bacterial isolation and identification {#sec005}
--------------------------------------

Urine samples were analysed and processed based on the microbiology laboratory standards \[[@pone.0164306.ref014]\]. For this study, a culture with presence of ≥10^7^ colony forming unit (cfu) per litre of urine was considered positive for UTI based on the laboratory recommendations. This 10^7^ cfu/L cut-off is commonly used as it increases the sensitivity of the urine culture test making it a practical threshold \[[@pone.0164306.ref015]\]. The criterion has also been used by several studies reporting on antimicrobial resistance of urinary *E*. *coli* \[[@pone.0164306.ref001],[@pone.0164306.ref016],[@pone.0164306.ref017]\]. Cultures with three or more bacterial species isolated were considered contaminated and excluded. Only the first positive *E*. *coli* UTI per patient per year was included in the final analysis.

Definitions {#sec006}
-----------

Urine cultures were classified based on the setting of acquisition of infection (hospital-acquired and community-acquired, also known as hospital-onset and community-onset) using criteria from the Centers for Disease Control and Prevention definitions \[[@pone.0164306.ref018]\]. Positive *E*. *coli* urine cultures obtained within the first 48 hours of admission (including cultures from non-admissions such as outpatient clinics) were defined as community-acquired UTIs. Positive cultures obtained more than 48 hours after admission and within 48 hours of discharge were defined as hospital-acquired UTIs.

Antimicrobial susceptibility testing {#sec007}
------------------------------------

Antimicrobial susceptibility was performed by a disc diffusion method and the automated minimum inhibitory concentration (MIC) method using Vitek2 (Biomerieux Diagnostics). Interpretation was based on Clinical Laboratory Standard Institute (CLSI, formerly NCCLS) criteria \[[@pone.0164306.ref019]\]. Based on a stepwise laboratory testing protocol used during the study period, all significant *E*. *coli* (\>10^7^cfu/L) isolated after overnight incubation on culture had disc susceptibility testing done. The antibiotic discs used for these tests were ampicillin (10μg), amoxycillin-clavulanate (augmentin) (30μg), cephalexin/cefazolin (30 μg), trimethoprim (5μg), nalidixic acid (30 μg), ciprofloxacin (5 μg), nitrofurantoin (300 μg) and gentamicin (10μg). The isolates which were found to be resistant to at least three of the routinely tested antibiotics were then sent for Vitek2 testing to determine the MICs for ceftriaxone, trimethoprim-sulphamethoxazole, meropenem and piperacillin-tazobactam in addition to the routinely tested antibiotics. Direct susceptibility testing method on urine specimens for *E*. *coli* has been validated at ACT Pathology and is comparable to the CLSI recommended methods.

The quality control strains used for disc diffusion tests were *E*. *coli* ATCC 25922, *E*. *faecalis* ATCC 29212 and for Vitek *E*. *coli* ATCC 25922, *P*. *aeruginosa* ATCC 27853, *E*. *faecalis* ATCC 29212, *S*. *aureus* ATCC 29213.

Extended spectrum beta lactamase (ESBL) confirmation {#sec008}
----------------------------------------------------

Detection of ESBL-producing isolates was performed with combination discs of cefotaxime (30μg), cefotaxime/clavulanic acid (30/10μg), ceftazidime (30μg) and ceftazidime/clavulanic acid (30/10μg) whenever required according to CLSI guidelines \[[@pone.0164306.ref015]\]. Extended spectrum beta lactamase production was inferred when the zone diameter of the disc with clavulanate was ≥5mm larger than the disc without clavulanate for the same antibiotic. *K*. *pneumoniae* ATCC 700603 was used as the quality control strain.

Statistical analysis {#sec009}
--------------------

The overall 5-year and yearly resistance rates of *E*. *coli* to the routinely tested first-line antimicrobials on over 4,000 isolates (ampicillin, amoxycillin-clavulanate, cephalexin/cefazolin, ciprofloxacin, gentamicin, nalidixic acid, and trimethoprim) were calculated by dividing the number of urinary *E*. *coli* isolates resistant to each antimicrobial by the number of isolates tested against an individual antimicrobial agent. For the isolates which were sent for further susceptibility testing on Vitek2 against second-line antimicrobials (ceftriaxone, trimethoprim-sulphamethoxazole, meropenem, piperacillin-tazobactam and nitrofurantoin), the denominator used in calculating the resistance rates was the total number of isolates included in the study. This denominator was used based on the assumption that isolates were initially not tested for the Vitek2 antibiotics because they were considered highly unlikely to be resistant to these antibiotics. Hence in order not to overestimate the resistance rates of these isolates the denominator included all isolates tested on both antibiotic discs and Vitek2. The binomial exact 95% confidence intervals (CI) of the resistance percentages were calculated. The 5-year resistance rates were compared for community- and hospital-acquired isolates. The chi-square test was used to check for statistically significant differences in AMR between both groups. Mean differences in age between the two groups were tested using Student's t-tests. A time series analysis was performed separately for all antimicrobials tested to identify patterns in resistance (trends and seasonal variation) over the five year period. Seasonality is a pattern that shows periodic repetitive fluctuations over time. An autoregressive (AR) model was constructed to assess time-varying resistance patterns (i.e., resistance is non-stationary, or changing, over time) and multiple time series models were fitted to also account for age and sex. The analysis on age and sex followed an ecological study design because these variables were aggregated for each season. The Dickey-Fuller (DF) and the augmented Dickey-Fuller (ADF) tests were used to assess a unit root in the time series data. Both DF and ADF statistics are negative numbers; the more negative, the stronger the rejection of the null hypothesis (that there is unit root at some level of confidence). These unit root tests investigate whether a time series variable (e.g., resistance) is non-stationary using the AR model \[[@pone.0164306.ref020]\]. Urinary *E*. *coli* isolates for which the antimicrobial showed an intermediate susceptibility category (amoxycillin-clavulanate, trimethoprim, and ciprofloxacin) were excluded from the final analysis. A significance level of *P* \< 0.05 was used. Data were analysed using STATA statistical software (version 13, StataCorp).

Results {#sec010}
=======

A total of 106,512 urine samples from 47,727 patients attending Canberra Hospital from 2009 to 2013 were processed by ACT Pathology. Of these, 14.1% (n = 15,022) had positive cultures with *E*. *coli* being the most common organism isolated in 7670 (51.1%) samples. The distribution of samples by study year is shown in [S1 Table](#pone.0164306.s001){ref-type="supplementary-material"}.

Of the 7670 *E*. *coli* cultures, most (7103 isolates) could be further classified as community- or hospital-acquired UTI based on available data. The data were then restricted to the first positive *E*. *coli* UTI per patient per year of which there were 5346 positive *E*. *coli* UTIs but only 5333 had susceptibility test results. Hence 5333 *E*. *coli* UTIs belonging to 4732 patients in the 5-year period were included in the final analysis. The majority (84.2%, n = 4492) of UTIs were classified as community-acquired and 15.8% (n = 841) as hospital-acquired. The mean age of all patients was 57.0 years (SD = 27.5) and patients were mostly female (80.2%, n = 3795). There was a significant difference in age between patients with hospital- and community-acquired *E*. *coli* UTI (mean age 67.2 years versus 55.1 years, P\<0.001) but no significant differences in gender.

Antimicrobial resistance {#sec011}
------------------------

All 5333 isolates had routine susceptibility testing performed against first-line antimicrobials and the overall 5-year and stratified (hospital- and community-acquired) AMR rates are summarised in [Table 1](#pone.0164306.t001){ref-type="table"}. Of the 5333 isolates, 1599 (29.9%) were sent for further antimicrobial susceptibility testing for second-line antimicrobials on Vitek2. The overall 5-year resistance rates to these second-line antimicrobials are reported in [Table 2](#pone.0164306.t002){ref-type="table"}.

10.1371/journal.pone.0164306.t001

###### Resistance profile of urinary *E*. *coli* isolates sent for routine susceptibility testing from 2009 to 2013 by setting.

![](pone.0164306.t001){#pone.0164306.t001g}

                   COMMUNITY   HOSPITAL   TOTAL                                                                          
  ---------------- ----------- ---------- ------------- ------------ ----- ------------ ------------ ------ ------------ ------------
  Ampicillin       2009        835        331 (39.6)    36.3--43.1   143   71 (49.7)    41.2--58.1   978    402 (41.1)   38.0--44.3
                   2010        897        358 (39.9)    36.7--43.2   182   70 (38.5)    31.4--45.9   1079   428 (39.7)   36.7--42.7
                   2011        1037       443 (42.7)    39.7--45.8   189   91 (48.2)    40.8--55.5   1226   534 (43.6)   40.8--46.4
                   2012        939        412 (43.9)    40.7--47.1   173   74 (42.8)    35.3--50.5   1112   486 (43.7)   40.8--46.7
                   2013        784        315 (40.2)    36.7--43.7   154   71 (46.1)    38.1--54.3   938    386 (41.2)   38.0--44.4
                   Total       4492       1859 (41.4)   39.9--42.8   841   377 (44.8)   41.4--48.3   5333   2236(41.9)   40.6--43.3
  AMC              2009        785        24 (3.1)      2.0--4.5     133   6 (4.5)      1.7--9.6     918    30 (3.3)     2.2--4.6
                   2010        832        49 (5.9)      4.4--7.7     172   11 (6.4)     3.2--11.2    1004   60 (6.0)     4.6--7.6
                   2011        981        61 (6.2)      4.8--7.9     170   17 (10.0)    5.9--15.5    1151   78 (6.8)     5.4--8.4
                   2012        895        71 (7.9)      6.2--9.8     161   19 (11.8)    7.3--17.8    1055   89 (8.4)     6.8--10.3
                   2013        754        58 (7.7)      5.9--9.8     145   23 (15.9)    10.3--22.8   899    81 (9.0)     7.2--11.1
                   Total       4247       263 (6.2)     5.5--6.9     781   76 (9.3)     7.7--12.0    5027   338 (6.7)    6.0--7.5
  Cefazolin        2009        821        60 (7.3)      5.6--9.3     129   14 (10.9)    6.1--17.5    950    74 (7.8)     6.2--9.7
                   2010        885        96 (10.9)     8.9--13.1    179   24 (13.4)    8.8--19.3    1064   120 (11.3)   9.4--13.3
                   2011        1019       103 (10.1)    8.3--12.1    178   30 (16.9)    11.7--23.2   1197   133 (11.1)   9.4--13.0
                   2012        917        82 (8.9)      7.2--11.0    168   26 (15.5)    10.4--21.8   1085   108 (10.0)   8.2--11.9
                   2013        776        89 (11.5)     9.3--13.9    151   30 (19.9)    13.8--27.1   927    119 (12.8)   10.8--15.2
                   Total       4418       430 (9.7)     8.9--10.6    805   124 (15.4)   13.0--18.1   5223   554 (10.6)   9.8--11.5
  Trimethoprim     2009        830        153 (18.4)    15.9--21.2   143   28 (19.6)    13.4--27.0   973    181 (18.6)   16.2--21.2
                   2010        897        172 (19.2)    16.6--21.9   181   33 (18.2)    12.9--24.6   1078   205 (19.0)   16.7--21.5
                   2011        1036       217 (20.9)    18.5--23.6   189   42 (22.2)    16.5--28.8   1225   259 (21.1)   18.9--23.5
                   2012        939        200 (21.3)    18.7--24.1   173   40 (23.1)    17.1--30.1   1112   240 (21.6)   19.2--24.1
                   2013        784        181 (23.1)    20.2--26.2   154   36 (23.4)    16.9--30.9   938    217 (23.1)   20.5--26.0
                   Total       4486       923 (20.6)    19.4--21.8   840   179 (21.3)   18.6--24.2   5326   1102(20.7)   19.6--21.8
  Nalidixic acid   2009        826        63 (7.6)      5.9--9.7     143   12 (8.4)     4.4--14.2    969    75 (7.7)     6.1--9.6
                   2010        892        73 (8.2)      6.5--10.2    182   12 (6.6)     3.5--11.2    1074   85 (7.9)     6.4--9.7
                   2011        1034       109 (10.5)    8.7--12.6    188   22 (11.7)    7.5--17.2    1222   131 (10.7)   9.0--12.6
                   2012        755        56 (7.4)      5.7--9.5     140   17 (12.1)    7.2--18.7    895    73 (8.2)     6.4--10.1
                   2013        585        33 (5.6)      3.9--7.8     103   11 (10.7)    5.5--18.3    688    44 (6.4)     4.7--8.5
                   Total       4092       334 (8.2)     7.3--9.0     756   74 (9.8)     7.8--12.1    4848   408 (8.4)    7.6--9.2
  Ciprofloxacin    2009        808        33 (4.1)      2.8--5.7     139   7 (5.0)      2.0--10.1    947    40 (4.2)     3.0--5.7
                   2010        701        35 (5.0)      3.5--6.9     150   4 (2.7)      0.7--6.7     851    39 (4.6)     3.3--6.2
                   2011        795        52 (6.5)      4.9--8.5     156   10 (6.4)     3.1--11.5    951    62 (6.5)     5.0--8.3
                   2012        749        56 (7.5)      5.7--9.6     143   11 (7.7)     3.9--13.3    892    67 (7.5)     5.9--9.4
                   2013        631        60 (9.5)      7.3--12.1    135   17 (12.6)    7.5--19.4    766    77 (10.1)    8.0--12.4
                   Total       3684       236 (6.4)     5.6--7.2     723   49 (6.8)     5.1--8.9     4407   285 (6.5)    5.8--7.2
  Gentamicin       2009        514        17 (3.3)      1.9--5.2     85    5 (5.9)      1.9--13.2    599    22 (3.7)     2.3--5.5
                   2010        893        23 (2.6)      1.6--3.8     182   2 (1.1)      0.1--3.9     1075   25 (2.3)     1.5--3.4
                   2011        1036       38 (3.7)      2.6--5.0     189   12 (6.4)     3.3--10.8    1225   50 (4.1)     3.0--5.3
                   2012        931        40 (4.3)      3.1--5.8     172   12 (7.0)     3.7--11.9    1102   52 (4.7)     3.5--6.1
                   2013        783        36 (4.6)      3.2--6.3     154   10 (6.5)     3.2--11.6    937    46 (4.9)     3.6--6.5
                   Total       4157       154 (3.7)     3.2--4.3     782   41 (5.2)     3.8--7.0     4938   195 (3.9)    3.4--4.5

\*Note that not all 5333 isolates were tested against each antimicrobial. Isolates not tested: AMC = 3; Cephazolin = 110; Trimethoprim = 3; Nalidixic acid = 485; Ciprofloxacin = 893; Gentamicin = 395

Number of isolates with intermediate susceptibility to an antimicrobial: AMC = 303; Trimethoprim = 4; Ciprofloxacin = 33

R = Resistant

n = Number of isolates

AMC = Amoxycillin-clavulanate; TMP-SMX = Trimethoprim-sulphamethoxazole

10.1371/journal.pone.0164306.t002

###### Resistance profile of urinary *E*. *coli* isolates sent for further testing on Vitek2 from 2009 to 2013 by setting.

![](pone.0164306.t002){#pone.0164306.t002g}

  Year    Setting   N      Antibiotic                                                                                                  
  ------- --------- ------ ------------ ----------- ------------ ------------ --------- ---------- ----------- ----------- ----------- ----------
  2009    CA        835    12 (1.4)     0.7--2.5    58 (6.9)     5.3--8.9     0 (0.0)   \-         2 (0.2)     0.0--0.9    14 (1.7)    0.9--2.8
          HA        143    2 (1.4)      0.2--5.0    12 (8.4)     4.4--14.2    0 (0.0)   \-         0 (0.0)     \-          4 (2.8)     0.8--7.0
          Total     978    14 (1.4)     0.8--2.4    70 (7.2)     5.6--9.0     0 (0.0)   \-         2 (0.2)     0.0--0.7    18 (1.8)    1.1--2.9
  2010    CA        897    22 (2.5)     1.5--3.7    76 (8.5)     6.7--10.5    0 (0.0)   \-         27 (3.0)    2.0--4.3    15 (1.7)    0.9--2.7
          HA        182    4 (2.2)      0.6--5.5    11 (6.0)     3.1--10.6    0 (0.0)   \-         4 (2.2)     0.6--5.5    5 (2.7)     0.9--6.3
          Total     1079   26 (2.4)     1.6--3.5    87 (8.1)     6.5--9.9     0 (0.0)   \-         31 (2.9)    2.0--4.1    20 (1.9)    1.1--2.8
  2011    CA        1037   46 (4.4)     3.3--5.9    99 (9.5)     7.8--11.5    0 (0.0)   \-         19 (1.8)    1.1--2.8    17 (1.6)    1.0--2.6
          HA        189    13 (6.9)     3.7--11.5   30 (15.9)    11.0--21.9   0 (0.0)   \-         9 (4.8)     2.2--8.8    3 (1.6)     0.3--4.6
          Total     1226   59 (4.8)     3.7--6.2    129 (10.5)   8.9--12.4    0 (0.0)   \-         28 (2.3)    1.5--3.3    20 (1.6)    1.0--2.5
  2012    CA        939    43 (4.6)     3.3--6.1    102 (10.9)   8.9--13.0    1 (0.1)   0.0--0.6   33 (3.5)    2.4--4.9    35 (3.7)    2.6--5.1
          HA        173    13 (7.5)     4.1--12.5   22 (12.7)    8.1--18.6    0 (0.0)   \-         15 (8.7)    4.9--13.9   5 (2.9)     0.9--6.6
          Total     1112   56 (5.0)     3.8--6.5    124 (11.1)   9.4--13.1    1 (0.1)   0.0--0.5   48 (4.3)    3.2--5.7    40 (3.6)    2.6--4.9
  2013    CA        784    45 (5.7)     4.2--7.6    87 (11.1)    9.0--13.5    0 (0.0)   \-         30 (3.8)    2.6--5.4    42 (5.4)    3.9--7.2
          HA        154    15 (9.7)     5.6--15.6   25 (16.2)    10.8--23.0   0 (0.0)   \-         16 (10.4)   6.1--16.3   4 (2.6)     0.7--6.5
          Total     938    60 (6.4)     4.9--8.2    112 (11.9)   9.9--14.2    0 (0.0)   \-         46 (4.9)    3.6--6.5    46 (4.9)    3.6--6.5
  Total   CA        4492   168 (3.7)    3.2--4.3    422 (9.4)    8.6--10.3    1 (0.0)   0.0--0.1   111 (2.5)   2.0--3.0    123 (2.7)   2.3--3.3
          HA        841    47 (5.6)     4.1--7.4    100 (11.9)   9.8--14.3    0 (0.0)   \-         44 (5.2)    3.8--7.0    21 (2.5)    1.6--3.8
          Total     5333   215 (4.0)    3.5--4.6    522 (9.8)    9.0--10.6    1 (0.0)   0.0--0.1   155 (2.9)   2.5--3.4    144 (2.7)   2.3--3.2

R = Resistant

N = Number of isolates tested

CA = Community isolates; HA = Hospital isolates

TMP-SMX = Trimethoprim-sulphamethoxazole; MER = Meropenem; PIT = Piperacillin-tazobactam; NIT = Nitrofurantoin

The highest overall 5-year resistance rates to urinary *E*. *coli* for both hospital and community isolates combined were seen for ampicillin (41.9%; 95% CI = 40.6--43.3) and trimethoprim (20.7%; 95% CI = 19.6--21.8). The lowest resistance rates were for meropenem (0.0%), nitrofurantoin (2.7%; 95% CI = 2.3--3.2) and piperacillin-tazobactam (2.9%; 95% CI = 2.5--3.4). Resistance to amoxycillin-clavulanate, cephalexin/cefazolin, gentamicin and piperacillin-tazobactam was significantly higher in hospital- compared to community-acquired UTIs (P\<0.001, P\<0.001, P = 0.043 and P = 0.002, respectively). For ampicillin, trimethoprim, nalidixic acid, ciprofloxacin, ceftriaxone and trimethoprim-sulphamethoxazole, resistance rates were also higher for hospital- compared with community-acquired UTI but this did not reach statistical significance ([Fig 1](#pone.0164306.g001){ref-type="fig"}).

![Five-year resistance rates of hospital- and community-acquired *E*. *coli* UTIs by selected antibiotics.\
amp = ampicillin; tri = trimethoprim; cef = cefazolin; amc = amoxycillin-clavulanate; cip = ciprofloxacin; pit = piperacillin-tazobactam; gen = gentamicin; nit = nitrofurantoin. \*\* 0.001 \< p value \< 0.05. \*\* p \< 0.001](pone.0164306.g001){#pone.0164306.g001}

Trend analysis showed a significant increase in resistance to amoxycillin-clavulanate, trimethoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, ceftriaxone and gentamicin over the five year period ([Fig 2](#pone.0164306.g002){ref-type="fig"}). There was no significant increase in resistance for ampicillin, nalidixic acid, meropenem and piperacillin-tazobactam. A seasonal pattern was only observed for trimethoprim (ADF statistic = -4.136; P = 0.006) with higher resistance rates for this antimicrobial seen in the summer months. Regression analysis indicated an association between increasing age and resistance to ciprofloxacin (regression coefficient = 0.01; P = 0.004), cefazolin (regression coefficient = 0.004; P = 0.038) and ceftriaxone (regression coefficient = 0.01; P = 0.002).

![Seasonal antimicrobial resistance rates for *E*. *coli* UTIs.\
1 = Summer; 2 = Autumn; 3 = Winter; 4 = Spring. P = significance level for an increasing trend. AMC = Amoxycillin-clavulanate; TMP-SMX = Trimethoprim-sulphamethoxazole](pone.0164306.g002){#pone.0164306.g002}

ESBL production {#sec012}
---------------

Overall 5-year prevalence of ESBL-producing *E*. *coli* isolates was 1.9% (95% CI = 1.5--2.3; n = 100). Extended spectrum beta-lactamase production was low by international standards but was significantly higher in hospital-acquired (3.0%; 95% CI = 1.9--4.4; n = 25) compared with community-acquired UTIs (1.7%; 95% CI = 1.3--2.1; n = 75, P = 0.01). The levels of ESBL-producing *E*. *coli* increased from 0.7% (95% CI = 0.0--3.8) in hospital-acquired UTIs in 2009 to 6.5% (95% CI = 3.2--11.6) in 2013. An increase was also noted for community-acquired UTIs (0.6%; 95% CI = 0.2--1.4 in 2009 to 3.7%; 95% CI = 2.5--5.3 in 2013). The increasing trend in ESBL production over the five years was statistically significant for both hospital (P = 0.035) and community-acquired UTIs (P\<0.001).

Discussion {#sec013}
==========

This study provides information about the AMR pattern of *E*. *coli* UTIs in an Australian tertiary hospital. To our knowledge this is the first Australian study to compare AMR in hospital- and community-acquired *E*. *coli* UTI and assess AMR temporal trends and seasonal variation of *E*. *coli* UTI over time. Our results showed that overall resistance was highest for ampicillin and trimethoprim. We also found significantly higher resistance rates in hospital- compared to community-acquired UTIs for amoxycillin-clavulanate, cephalexin/cefazolin, gentamicin and piperacillin-tazobactam with an increasing resistance trend for eight of the twelve antimicrobials tested which include the four commonly used antimicrobials for first line treatment of UTI in Australia.

In Australia, trimethoprim, cephalexin, amoxycillin-clavulanate or nitrofurantoin are recommended for first line treatment of UTI \[[@pone.0164306.ref021]\]. The Infectious Diseases Society of America (IDSA) and European Society for Microbiology and Infectious Diseases recommend trimethoprim-sulphamethoxazole as an appropriate treatment choice if local resistance rates do not exceed 20%. The IDSA guidelines also recommend that amoxycillin or ampicillin should not be used alone for empirical treatment because of the relatively poor efficacy and the relatively high prevalence of AMR to these agents worldwide \[[@pone.0164306.ref022]\]. Given the high levels of resistance to ampicillin and trimethoprim identified in this study, the appropriateness of these antimicrobials in the management of UTI in this patient population should be assessed. The IDSA suggests that beta-lactam agents, including amoxycillin-clavulanate are appropriate choices for therapy when other recommended agents cannot be used \[[@pone.0164306.ref022]\]. Based on our findings, the majority of UTIs have very low resistance to amoxycillin-clavulanate and nitrofurantoin which are commonly used for UTI treatment in Canberra. Ciprofloxacin, which is recommended in Australia for complicated UTIs, was also found to have a low resistance rate. Through the national pharmaceutical subsidy scheme, the use of quinolones in humans has been restricted in Australia. Quinolone use in food-producing animals is also not permitted. Therefore, fluoroquinolone resistance in the community has been slow to emerge and has remained at low levels in important pathogens such as *E*. *coli* compared to most countries \[[@pone.0164306.ref023]\]. Our overall resistance rates are also generally lower than reported for other single site studies \[[@pone.0164306.ref009],[@pone.0164306.ref024]\], demonstrating that resistance may vary geographically, as shown in a recent meta-analysis \[[@pone.0164306.ref025]\]. The explanation for the varying resistance rates is not clearly understood but possible reasons have been postulated. A study conducted in the United States demonstrated a geographic gradient in resistance with the highest resistance rates noted in the Pacific region and lowest rates in the South Atlantic region \[[@pone.0164306.ref026]\]. It was suggested that geographic clustering of resistance phenotypes may have accounted for the geographic differences in resistance. It is therefore possible that the lower rates we found in comparison to those reported for other single site studies may be due to lower levels of bacteria with resistance phenotypes in our locality. Another possible suggestion for geographic variation in resistance is the differences in antimicrobial use \[[@pone.0164306.ref026],[@pone.0164306.ref027]\]. Several studies have demonstrated an association between antimicrobial use and resistance \[[@pone.0164306.ref028]--[@pone.0164306.ref030]\]. Hence it is probable that the lower resistance noted may be as a result of lower antimicrobial use resulting in lower antimicrobial selection pressure. This emphasizes the need for continuous local monitoring of resistance patterns to ensure appropriate treatment for people in the locality.

The sample size of the data was able to detect some significant differences between community- and hospital-acquired UTI resistance rates but for some antimicrobials the differences observed could not be confirmed statistically, possibly due to an insufficient sample size. Overall, we found lower rates of antibiotic resistance for community- compared with hospital-acquired *E*. *coli* UTIs, consistent with other studies \[[@pone.0164306.ref009],[@pone.0164306.ref031]\]. The difference in resistance rates is however only small and supports the view that *E*. *coli*, a bacterium carried in the bowel and acquired in the community, is brought into hospital usually by patients themselves rather than being hospital-acquired. This finding may also have been partially dictated by our methodology from using the first positive UTI per person per year. The different resistance rates for hospital- and community-acquired urinary *E*. *coli* isolates seen in this study are comparable with findings reported previously \[[@pone.0164306.ref010],[@pone.0164306.ref011]\]. Similar results have been seen in blood culture isolates of *E*. *coli* in Canberra \[[@pone.0164306.ref032]\]. While the difference in resistance rates was not large and most antimicrobial use occurs in the community, the proportion of patients receiving antimicrobials is much higher in the hospital and hence explains the difference seen \[[@pone.0164306.ref033]\]. We agree with recommendations that to accurately represent *E*. *coli* resistance rates, antibiograms should be stratified by setting of infection onset \[[@pone.0164306.ref034]\].

The increasing resistance trend noted in our study for the eight antimicrobials is consistent with previously reported Australian data and published studies from other developed countries \[[@pone.0164306.ref006],[@pone.0164306.ref007],[@pone.0164306.ref009],[@pone.0164306.ref035],[@pone.0164306.ref036]\]. The increasing trend may be attributable to antimicrobial overuse or misuse which is a known risk factor for the development of AMR \[[@pone.0164306.ref037]\]. However, clinical data on hospital antimicrobial use at the study location showed stable rates for most antimicrobials tested (data not shown). We also found seasonal increases in trimethoprim resistance especially in summer months. The literature suggests a possible seasonality with UTI incidence \[[@pone.0164306.ref038],[@pone.0164306.ref039]\] but this was not demonstrated in our study. It is possible that seasonality in UTI may lead to seasonal variation in antimicrobial use with subsequent seasonal resistance patterns although to our knowledge, this is yet to be demonstrated in published studies. Evidence currently exists to show higher use of antimicrobials in winter months which is likely related to the increased incidence of respiratory tract infections during that period with consequent increases in resistance during winter \[[@pone.0164306.ref040],[@pone.0164306.ref041]\]. Therefore the seasonal trimethoprim resistance is a potentially important finding which should be explored in future studies especially in relation to antimicrobial use. The ecological analysis conducted in this study showed an association between older age and resistance to ciprofloxacin, cefazolin and ceftriaxone consistent with published studies \[[@pone.0164306.ref006],[@pone.0164306.ref034],[@pone.0164306.ref042]\]. The association between increasing age and increased resistance is not surprising given that the physiological changes caused by aging and increased comorbidities predispose to a higher risk of infection leading to more contact with healthcare settings and hence more frequent exposure to antibiotics \[[@pone.0164306.ref042]\].

It is worth emphasizing that our overall ESBL rate of 1.9% was low compared to most other published studies \[[@pone.0164306.ref031]\]. Results from the 2009--2011 SMART study in the United States reported an ESBL rate of 6.8% for *E*. *coli* UTI \[[@pone.0164306.ref031]\]. Although our reported ESBL rate is relatively low, the presence and increasing trend of ESBL-producing *E*. *coli* in both hospital and community-acquired UTIs pose considerable public health concern. This is because this organism renders many of the conventional empirical treatment options for UTI ineffective especially in community-acquired UTI where options for oral antibiotic therapy appear to be limited \[[@pone.0164306.ref043]\]. For hospital-acquired UTI caused by ESBL-producing *E*. *coli*, carbapenems are considered the treatment of choice \[[@pone.0164306.ref043]\]. In our study, the lowest resistance rate reported was for meropenem, a carbapenem.

This study has some limitations. As most UTIs are treated empirically, it is possible that samples submitted to the laboratory included patients with recurrent UTIs and asymptomatic bacteriuria thereby overestimating the resistance rates. In addition, inclusion of the first positive *E*. *coli* UTI per person per year may have underestimated the resistance rates reported in our study. Evidence suggests that analysis of antimicrobial resistance data should include each individual positive isolate in order to ensure sensitivity, but this positive isolate should only be included once to guarantee specificity \[[@pone.0164306.ref044]\]. This approach of using only the first positive isolate per patient per year is also consistent with published studies on resistance in UTI pathogens including *E*. *coli* \[[@pone.0164306.ref017],[@pone.0164306.ref034]\]. It is unlikely that repeated isolates are correlated but there is a small possibility that this could occur although it was not accounted for in the analysis. The 5-year period prevalence study could therefore have overestimated the resistance. The use of routinely collected microbiology data also posed some limitations as clinical information on patients including comorbidities and presence of indwelling urethral catheters was often missing. The incompleteness of this information prevented its inclusion in the analysis. This study was based on retrospective antimicrobial susceptibility data from a National Association of Testing Authorities, Australia (NATA) accredited clinical microbiology laboratory. The stepwise laboratory testing protocol involved routine first-line antibiotic sensitivity testing followed by more extensive testing with second-line antibiotics only for isolates resistant to at least three of the routine antibiotics. Although this laboratory approach is widely used \[[@pone.0164306.ref044]\] there is the potential for testing bias and/or selection bias with consequent overestimation of resistance rates. Given the lack of consensus on an appropriate denominator using this testing approach and to prevent possible overestimation of the resistance rates against second-line antibiotics, the denominator therefore included all isolates tested, which, in turn, may have under-estimated resistance rates of broad spectrum antimicrobials. Determining the resistance rate can be influenced by the extent of laboratory testing which in turn influences the selection of the denominator. Using the total number of isolates tested or the number of isolates tested against second-line antibiotics alone as the denominator will either underestimate or overestimate the resistance rates respectively. Although using all isolates for calculating resistance rates for second-line antibiotics has its limitations, this was an appropriate denominator choice to make the findings relevant for use in the clinical setting. For ideal comparison of susceptibility patterns, all isolates would need to be tested against the extended panel of antibiotics in a properly designed prospective study. Regardless of these limitations, our reported resistance rates are low compared to other studies. The use of ecological data to account for the effects of age and sex on resistance also poses limitations to interpretation of these results at the individual patient level. Although our data are from a single tertiary hospital and may not be generalisable to other populations, the data were reported by a NATA accredited laboratory and are therefore satisfactory to provide recommendations to guide local empirical therapy.

Conclusions {#sec014}
===========

Antimicrobial resistance poses grave concerns for antimicrobial effectiveness in treating infections such as UTI. This study demonstrates the increasing resistance of urinary *E*. *coli* to commonly prescribed antimicrobials. Amoxycillin-clavulanate and nitrofurantoin are still effective for empirical treatment of UTI in this population. Overuse of ampicillin and trimethoprim should be avoided given the high resistance rates reported. In developing local antimicrobial prescribing guidelines, the choice of antimicrobial in the treatment of UTI should be based on setting (community or hospital) of acquisition.
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